@article{2f880f533e7544a5ad8ba74673fa6f4f,
title = "Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014",
abstract = "Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.",
keywords = "AD biomarker signature, Alzheimer's disease, Amyloid phenotyping, Clinical trial biomarkers, Data-sharing, Tau imaging, Worldwide ADNI",
author = "Weiner, {Michael W.} and Veitch, {Dallas P.} and Aisen, {Paul S.} and Beckett, {Laurel A.} and Cairns, {Nigel J.} and Jesse Cedarbaum and Donohue, {Michael C.} and Green, {Robert C.} and Danielle Harvey and Jack, {Clifford R.} and William Jagust and Morris, {John C.} and Petersen, {Ronald C.} and Saykin, {Andrew J.} and Leslie Shaw and Thompson, {Paul M.} and Toga, {Arthur W.} and Trojanowski, {John Q.}",
note = "Funding Information: John Morris has participated or is currently participating in clinical trials of antidementia drugs sponsored by the following companies: Janssen Immunotherapy, Pfizer, Eli Lilly/Avid Radiopharmaceuticals, SNIFF (The Study of Nasal Insulin to Fight Forgetfulness) study, and A4 (The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) trial. Dr. Morris has served as a consultant for Lilly USA, ISIS Pharmaceuticals, and Charles Dana Foundation. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants #P50AG005681; P01AG003991; P01AG026276; and U19AG032438. Funding Information: Laurel A. Beckett receives funding from the following NIH grants: 2P30CA093373-11 (deVere White, Ralph), 2P30AG010129-23 (deCarli, Charles), 5U01AG024904-09 (Weiner), 5R01CA159447-02 (Miller, Lisa), and 5P30AG043097-02 (Hinton, Ladson). In addition, she has received funding from the following California Breast Cancer Research Program grant: CBCRP # 16BB-1600 (von Friederichs-Fitzwater). She also has received funding from the nonprofit Critical Path Institute (Arizona) for consultation on analysis of potential biomarkers for Alzheimer's disease clinical trials. Funding Information: Paul M. Thompson has received funding, in addition to ADNI, from the NIA, NIMH, NINDS, and from the NIH Big Data Centers of Excellence program (U54 EB 020403), which is funded by several NIH agencies including NIBIB and NCI. Funding Information: Clifford R. Jack has provided consulting services for Janssen Research & Development, LLC, and Eli Lilly. He receives research funding from the National Institutes of Health (R01-AG011378, U01-HL096917, U01-AG024904, RO1 AG041851, R01 AG37551, R01AG043392, U01-AG06786), and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. Funding Information: Danielle Harvey is Associate Editor for Statistics for the Journal of Alzheimer Disease and Associated Disorders, on the Statistical Advisory Board for PLoS ONE, and on the Advisory Board for Eye & Contact Lens. She receives funding from NIH (5P30AG010129-21, 2U01AG024904-06, 5R01HD042974-08, 1U54NS079202-01, 1U54HD079125-01) and DOD (W81XWH-12-2-0012, W81XWH-13-1-0259). Publisher Copyright: {\textcopyright} 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.",
year = "2015",
month = jul,
day = "1",
doi = "10.1016/j.jalz.2015.04.005",
language = "English (US)",
volume = "11",
pages = "865--884",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "7",
}